Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial

High Event Rate After a First Percutaneous Coronary Intervention in Patients With Diabetes Mellitus

“…The incidence of a cardiovascular cause of mortality was ≈60% in those with diabetes mellitus, as opposed to the 70% to 80% that are usually described in many elderly recruited cohorts. 25 Therefore, there seems to have been a reduction in causes of mortality from cardiovascular disease in patients with diabetes mellitus, described as being ≈70% to 80% in those with a MI in the 1990s, to ≈60% in a modern population like that at the present time.…”

The clinical burden of type 2 diabetes in patients with acute coronary syndromes: Prognosis and implications for short- and long-term management

“…A recently published 20-year follow-up of the DIGAMI 1 trial showed that intensive insulin-based glycaemic control for 3 months after an initial acute MI in patients with type 2 diabetes increased survival by 2.3 years compared with standard glycaemic control, with the mortality benefit most apparent within the first 8 years. 39 A number of studies have investigated the effect of glucose-insulin-potassium (GIK) infusion in the acute post-ACS setting. The concept of metabolic modulation by GIK was based on the ability of insulin to suppress free fatty acid levels and stimulate potassium uptake, thereby facilitating glucose transport into cells.…”

Glycemia control and glucose-lowering therapy in patients with type 2 diabetes mellitus and cardiovascular disease (review of multicenter randomized trials)

“…В исследовании DIGAMI [2,18] изучено влияние ин-сулина на смертность при ОИМ у лиц с СД2. Пациентам вводили внутривенно в течение 24 часов глюкозо-ин-сулиновую смесь, а затем в течение 3 месяцев -инсу-лин подкожно.…”

“…В 2014 г. опубликованы результаты исследования DIGAMI, средний срок наблюдения которого составил 7,3 года [18]. За это время в группе пациентов, получав-ших глюкозо-инсулиновую смесь, смертность составила 89%, в контрольной группе -91%.…”